Thomas Gréa, Guillaume Jacquot, Arthur Durand, Clélia Mathieu, Adeline Gasser, Chen Zhu, Mainak Banerjee, Elyse Hucteau, Joris Mallard, Pedro Lopez Navarro, Bogdan V Popescu, Eloise Thomas, David Kryza, Jacqueline Sidi-Boumedine, Giuseppe Ferrauto, Eliana Gianolio, Guillaume Fleith, Jérôme Combet, Susana Brun, Stéphane Erb, Sarah Cianferani, Loïc J Charbonnière, Lyne Fellmann, Céline Mirjolet, Laurent David, Olivier Tillement, François Lux, Sébastien Harlepp, Xavier Pivot, Alexandre Detappe
Subcutaneous (SC) administration of monoclonal antibodies (mAbs) is a proven strategy for improving therapeutic outcomes and patient compliance. The current FDA-/EMA-approved enzymatic approach, utilizing recombinant human hyaluronidase (rHuPH20) to enhance mAbs SC delivery, involves degrading the extracellular matrix's hyaluronate to increase tissue permeability. However, this method lacks tunable release properties, requiring individual optimization for each mAb. Seeking alternatives, physical polysaccharide hydrogels emerge as promising candidates due to their tunable physicochemical and biodegradability features...
December 17, 2023: Advanced Materials